People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fuse Oncology, Inc. | — | Pharma | Series A | $11.8M | $79.4M | 2023 |
David Wiant at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Wiant on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Miller | 1 | 27 |
| Jay Brennan | 1 | 2 |
| James Bauler | 1 | 2 |
| Benjamin Sintay | 1 | 1 |
| John Strider | 1 | 1 |
| David Wiantt | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.